1.5T MRI引导放疗治疗局限性前列腺癌的早期卫生经济学分析:决策分析模型
本研究采用状态转移模型,从荷兰医疗视角评估1.5T MR-Linac(5次分割)相比5、20、39次外照射放疗(EBRT)和低剂量率近距离治疗(LDR)治疗局限性前列腺癌的成本效果。结果显示,在每患者€6460成本下,MR-Linac相比20次和39次EBRT无需降低并发症即可具有成本效果;相比5次EBRT和LDR,需分别相对降低并发症54%和66%才具成本效果。结果对泌尿、肠道和性功能并发症的效用值及生化进展概率高度敏感。
要点
- MR-Linac(5次)在€6460/患者成本下,相比20次和39次EBRT无需降低并发症即具成本效果。
- 相比5次EBRT和LDR近距离治疗,MR-Linac需分别相对降低并发症54%和66%才具成本效果。
- 结果对泌尿、肠道、性功能并发症效用值及生化进展概率高度敏感。
核心结论
- MR-Linac相比20次和39次EBRT在基线时即具成本效果。
- MR-Linac要优于5次EBRT和LDR近距离治疗,需大幅降低并发症或降低价格。
研究设计与样本
- 针对局限性前列腺癌男性的状态转移模型。
- 并发症率与效用值基于系统文献检索,成本从荷兰医疗视角估算。
- 采用阈值分析确定MR-Linac具成本效果的并发症与成本阈值,并进行单因素敏感性分析。
主要发现
- 在每患者€6460成本下,MR-Linac相比20次和39次EBRT无需降低并发症即具成本效果。
- 相比5次EBRT,MR-Linac需相对降低并发症54%才具成本效果。
- 相比LDR近距离治疗,MR-Linac需相对降低并发症66%才具成本效果。
- 结果对泌尿、肠道和性功能并发症的效用值及生化进展概率高度敏感。
关键数值与推荐
- MR-Linac成本为每患者€6460。
- MR-Linac相比5次EBRT的成本效果阈值:并发症相对降低54%。
- MR-Linac相比LDR近距离治疗的成本效果阈值:并发症相对降低66%。
临床怎么用
- 在荷兰医疗视角下,MR-Linac(5次)相比20次和39次EBRT可优先考虑成本效果。
- 若计划替代5次EBRT或LDR近距离治疗,需确保并发症大幅降低或协商更低价格。
- 决策时应重点关注泌尿、肠道、性功能并发症效用值及生化进展概率的本地数据。
局限性
- 临床证据缺乏,模型参数基于系统文献检索而非头对头临床研究。
- 分析为早期卫生经济学评价,结果对效用值和生化进展概率高度敏感。
- 成本估算基于荷兰医疗视角,外推至其他医疗体系需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: 1.5 Tesla magnetic resonance imaging radiotherapy linear accelerator (MR-Linac) is gaining interest for treatment of localized prostate cancer. Clinical evidence is lacking and it therefore remains uncertain whether MR-Linac is cost-effective. An early health economic analysis was performed to calculate the necessary relative reduction in complications and the maximum price of MR-Linac (5 fractions) to be cost-effective compared to 5, 20 and 39 fractionation schedules of external beam radiotherapy (EBRT) and low-dose-rate (LDR) brachytherapy. MATERIALS AND METHODS: A state transition model was developed for men with localized prostate cancer. Complication rates such as grade ≥2 urinary, grade ≥2 bowel and sexual complications, and utilities were based on systematic literature searches. Costs were estimated from a Dutch healthcare perspective. Threshold analyses were performed to identify the thresholds of complications and costs for MR-Linac to be cost-effective, while holding other outcomes such as biochemical progression and mortality constant. One-way sensitivity analyses were performed to outline uncertainty outcomes. RESULTS: At €6460 per patient, no reductions in complications were needed to consider MR-Linac cost-effective compared to EBRT 20 and 39 fractions. Compared to EBRT 5 fractions and LDR brachytherapy, MR-Linac was found to be cost-effective when complications are relatively reduced by 54% and 66% respectively. Results are highly sensitive to the utilities of urinary, bowel and sexual complications and the probability of biochemical progression. CONCLUSIONS: MR-Linac is found to be cost-effective compared to 20 and 39 fractions EBRT at baseline. For MR-Linac to become cost-effective over 5 fractions EBRT and LDR brachytherapy, it has to reduce complications substantially or be offered at lower costs.
引用
- Hehakaya C, van der Voort van Zyp JRN, Vanneste BGL, et al. Early health economic analysis of 1.5 T MRI-guided radiotherapy for localized prostate cancer: Decision analytic modelling. Radiother Oncol. 2021. PMID: 34089754. doi:10.1016/j.radonc.2021.05.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。